On behalf of the Society, I would like to welcome all of you to our first International Symposium.
The significance of experimentally induced proliferative hepatocellular changes in rodents for determining carcinogenic risk assessment in humans is a major problem for practicing toxicologic pathologists, academic experimental pathologists and the many diverse regulatory bodies throughout the world.
Drug and chemically induced hepatic nodules in mice and rats are relatively common microscopic findings seen by industrial pathologists and the fate of new pharmaceutical and chemical agents often resides in the histopathological evaluation of these findings.
The definitive morphologic characteristics of these hepatocellular changes have been the subject of many excellent symposia in the past, so we will attempt to address the significance of rodent liver nodules from the standpoint of our current level of experimental and human experience relative to human cancer risk.
In recent years, there has been a trend by a segment of the scientific community to consider the occurrence of rodent liver nodules as a precursor or predictor of carcinogenic potential in man. Another segment of the scientific community considers hepatic nodules in the rodent to be merely reactive responses to a wide variety of toxic stimuli and they feel that additional alterations must be observed in order to incriminate a particular test substance as being a carcinogen.
Most of the evidence presented in favor of liver nodules being neoplastic has been generated from studies using compounds which are highly active rodent carcinogens. These compounds induce hepatic tumors in twelve Presented at the International Symposium of the Society of Toxicologic Pathologists, Reston, Virginia, May 10-12, 1982.
1 months or less and usually develop into morphologically malignant neoplasms.
In contrast, industrial screening has eliminated compounds with such a high degree of hepatocellular activity through shorter term toxicity tests. Therefore most of the proliferative hepatic changes actually found in safety assessment studies are not apparent until eighteen to twenty-four months after continuous systemic exposure to the test substance.
The delayed appearance of these lesions into the geriatric period of the animal's life has raised the question that this type of hepatocellular proliferation may represent a beneficial stimulation of the detoxification or metabolic processes rather than a life threatening challenge. It is true that many of the compounds which are known to produce these long term effects are inducers of hepatic microsomal enzyme systems and in shorter term studies cause dramatic increases in liver weight with morphological evidence of centrolobular hepatocytic hypertrophy, cytoplasmic vacuolation and sinusoidal dialation.
Under these conditions, it has long been argued that reversibility of the lesions would support a diagnosis of hyperplasia over neoplasia, so one of our goals in the next two and a half days is to address the issue of reversibility of so called neoplastic nodules and then in turn, address the applicability of the term neoplastic nodule which by current definition includes both hyperplastic and neoplastic cellular changes. Both of these points are critical to the interpretation of rodent liver nodules for extrapolation to human risk assessment, particularly in the regulatory environment where tumor and non-tumor terminology must be legally concise.
We are extremely honored to have such a distinguished group of speakers representing academia, industry and regulatory agencies from the United States and abroad. As you KING TOXICOLOGIC PATHOLOGY can see from the program, the agenda has been divided into segments which will hopefully provide the basis for the Panel discussion on the final day of the Symposium.
Specifically, the speakers will address Diagnostic Criteria today to include Morphological, Biochemical, Physical and Nutritional considerations with tomorrow's session being devoted to Spontaneous and Chemically Induced Liver Foci and Nodules with separate categories to address Spontaneous Liver Changes in Rodents and Humans, Induced Liver Changes-Tumor Correlation between Rodents and Humans and finally, Induced Liver Changes-No Tumor Correlation to Humans.
The Panel will address the issue of the significance of rodent liver nodules for human cancer risk assessment and will then open the discussion to contributions from the floor.
Again. I welcome you and now I would like to introduce Dr. Michael latropoulos who will chair today's session.
